STOCK TITAN

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

Crinetics Pharmaceuticals (Nasdaq: CRNX) has announced that its Compensation Committee granted stock option awards to eleven new non-executive employees on November 10, 2024. The awards, totaling 99,500 shares, were granted under the 2021 Employment Inducement Incentive Award Plan at an exercise price of $60.69 per share. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment. These grants were made as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals (Nasdaq: CRNX) ha annunciato che il suo Comitato per la Compensazione ha concesso assegnazioni di opzioni sui titoli a undici nuovi dipendenti non esecutivi il 10 novembre 2024. Le assegnazioni, per un totale di 99.500 azioni, sono state concesse nell'ambito del Piano di Incentivazione per l'Occupazione del 2021 a un prezzo di esercizio di $60,69 per azione. Le opzioni si matureranno nell'arco di quattro anni, con il 25% che matura dopo un anno e il restante che matura mensilmente per 36 mesi, a condizione di continuare l'impiego. Questi conferimenti sono stati effettuati come incentivi all'occupazione in conformità con la Regola 5635(c)(4) del Nasdaq.

Crinetics Pharmaceuticals (Nasdaq: CRNX) ha anunciado que su Comité de Compensación otorgó opciones sobre acciones a once nuevos empleados no ejecutivos el 10 de noviembre de 2024. Las opciones, que totalizan 99,500 acciones, se concedieron bajo el Plan de Incentivos por Empleo de 2021 a un precio de ejercicio de $60.69 por acción. Las opciones se consolidarán durante cuatro años, con un 25% que se consolidará después de un año y el resto consolidándose mensualmente durante 36 meses, sujeto a continuar en el empleo. Estas concesiones se realizaron como incentivos de empleo de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq.

Crinetics Pharmaceuticals (Nasdaq: CRNX)는 2024년 11월 10일에 보상위원회가 11명의 신규 비임원 직원에게 주식 옵션 부여를 했다고 발표했습니다. 총 99,500주의 주식이 2021년 고용 유도 인센티브 부여 계획에 따라 $60.69의 행사 가격으로 부여되었습니다. 옵션은 4년에 걸쳐 배분되며, 1년 후에 25%가 배분되고 나머지는 36개월에 걸쳐 매달 배분됩니다. 이는 지속적인 고용을 조건으로 합니다. 이러한 부여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 고용 유도로 이루어졌습니다.

Crinetics Pharmaceuticals (Nasdaq: CRNX) a annoncé que son Comité de Compensation a accordé des attributions d'options sur actions à onze nouveaux employés non exécutifs le 10 novembre 2024. Les attributions, totalisant 99 500 actions, ont été accordées dans le cadre du Plan d'Incentives pour l'Emploi de 2021 à un prix d'exercice de $60,69 par action. Les options se déverrouilleront sur une période de quatre ans, avec 25 % se déverrouillant après un an et le reste se déverrouillant mensuellement sur 36 mois, sous réserve d'une poursuite d'emploi. Ces attributions ont été faites en tant qu'incitations à l'emploi conformément à la Règle de Cotation 5635(c)(4) de Nasdaq.

Crinetics Pharmaceuticals (Nasdaq: CRNX) hat bekannt gegeben, dass sein Vergütungsausschuss am 10. November 2024 Aktienoptionsvergaben an elf neue nicht-executive Mitarbeiter vergeben hat. Insgesamt wurden 99.500 Aktien im Rahmen des 2021 Beschäftigungsanreiz-Incentive-Programms zu einem Ausübungspreis von $60,69 pro Aktie gewährt. Die Optionen werden über vier Jahre hinweg vesten, wobei 25% nach einem Jahr und der Rest monatlich über 36 Monate vestet, vorbehaltlich einer fortlaufenden Beschäftigung. Diese Gewährungen wurden als Beschäftigungsanreize gemäß der Nasdaq-Listing Regel 5635(c)(4) vorgenommen.

Positive
  • Stock options granted at market price ($60.69), indicating alignment with current shareholder value
  • Four-year vesting schedule promotes employee retention and long-term commitment
  • Successful attraction of eleven new employees indicating company growth
Negative
  • Potential future dilution of existing shareholders from 99,500 new stock options

SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 99,500 shares of its common stock to eleven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2021 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $60.69 per share, which is equal to the closing price of Crinetics’ common stock on The Nasdaq Global Select Market on November 8, 2024. The shares subject to the stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each employee’s continued employment with Crinetics on such vesting dates. The options are subject to the terms and conditions of the 2021 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is an investigational, first-in-class, oral, once-daily somatostatin receptor type 2 (SST2) agonist in Phase 3 clinical development for acromegaly and in Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. 

Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340

Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 450-6464


FAQ

How many shares were granted in Crinetics (CRNX) November 2024 inducement grants?

Crinetics granted stock options for 99,500 shares to eleven new non-executive employees.

What is the exercise price for CRNX's November 2024 inducement stock options?

The exercise price is $60.69 per share, equal to CRNX's closing price on Nasdaq on November 8, 2024.

What is the vesting schedule for CRNX's November 2024 inducement grants?

The options vest over 4 years, with 25% vesting after one year and the remainder vesting in 36 monthly installments.

Crinetics Pharmaceuticals, Inc.

NASDAQ:CRNX

CRNX Rankings

CRNX Latest News

CRNX Stock Data

5.17B
89.30M
1.8%
94.69%
7.71%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO